In collaboration with the National Institutes of Health Maternal Fetal Medicine Network, Sera's scientific cofounders, Steven W. Graves, Ph.D., a professor in the department of Chemistry and Biochemistry at Brigham Young University and M. Sean Esplin, M.D., an associate professor and high-risk obstetrician at the University of Utah School of Medicine, identified biomarkers detectable from simple blood tests that can help predict the likelihood of preterm delivery and other pregnancy complications. Sera Prognostics has exclusively licensed rights to the preterm birth and preeclampsia biomarkers and the proteomics discovery technology for use in developing diagnostics to help predict and manage pregnancy complications.